Risk factors for metabolic bone disease in Crohn's disease patients

Inflammatory Bowel Diseases

Volumn 16, Issue 12, 2010, Pages 2117-2124

  Cravo, Marília ^a   Guerreiro, Catarina Sousa ^b   Dos Santos, Paula Moura ^c   Brito, Miguel ^b   Ferreira, Paula ^b   Fidalgo, Catarina ^a   Tavares, Lourdes ^c   Pereira, António Dias ^a  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^b Escola Superior de Tecnologia da Sade de Lisboa   (Portugal)

^c HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Crohn's disease; etiologic factors; metabolic bone disease

Indexed keywords

AZATHIOPRINE; BUDESONIDE; INTERLEUKIN 1; INTERLEUKIN 6; MONOUNSATURATED FATTY ACID; POLYUNSATURATED FATTY ACID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLELE; ARTICLE; BODY MASS; BONE DENSITY; CASE CONTROL STUDY; CHRONIC DISEASE; CLINICAL EVALUATION; COLON RESECTION; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FAT INTAKE; FEMALE; GENETIC ALGORITHM; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC BONE DISEASE; NUTRITIONAL ASSESSMENT; OSTEOPOROSIS; PHENOTYPE; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; VITAMIN INTAKE; VITAMIN K DEFICIENCY;

ADULT; BODY COMPOSITION; BODY MASS INDEX; BONE DENSITY; BONE DISEASES, METABOLIC; CASE-CONTROL STUDIES; CROHN DISEASE; FEMALE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; MALE; POLYMORPHISM, GENETIC; RISK FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649595800     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21297     Document Type: Article

References (35)

1. Adachi JD, Rostom A,. Metabolic bone disease in adults with inflammatory bowel disease. Inflamm Bowel Dis. 1999; 5: 200-211.
2. Ali T, Lam D, Bronze MS, Humphrey MB,. Osteoporosis in inflammatory bowel disease. Am J Med. 2009; 122: 599-604.
3. Bjarnson I,. Metabolic bone disease in patients with inflammatory bowel disease. Rheumatology. 1999; 38: 801-306.
4. Siffledeen JS, Fedorak RN, Siminoski K, et al. Risk factors associated with low bone mineral density in patients with Crohn's disease. Inflamm Bowel Dis. 2004; 10: 220-228.
5. Reid IR,. Glucocorticoid osteoporosis-mechanisms and management. Eur J Endocrinol. 1997; 137: 209-217.
6. Sousa-Guerreiro C, Cravo M, Costa AB, et al. A comprehensive approach to evaluate nutritional status in Crohn's patients in the era of biologic therapy: a case-control study. Am J Gastroenterol. 2007; 102: 2551-2556.
7. Lanham-New SA,. Importance of calcium, vitamin D and vitamin K for osteoporosis prevention and treatment. Proc Nutr Soc. 2008; 67: 163-176.
8. Sanada K, Miyachi M, Tabata I, et al. Differences in body composition and risk of life style-related diseases between young and older male rowers and sedentary controls. J Sports Sci. 2009; 27: 1027-1034.
9. Bernstein M, Irwin S, Greenberg GR,. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol. 2005; 100: 2031-2035.
10. Fiocchi C,. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998; 115: 182-205.
11. Cominelli F, Pizarro TT,. Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease. Aliment Pharmacol Ther. 1996; 10: 49-53.
12. Manolagas SC, Jilka RL,. Bone marrow, cytokines and bone remodeling. N Engl J Med. 1995; 332: 305-311.
13. Manolagas SC,. Role of cytokines in bone resorption. Bone. 1995; 17: 63S-67S.
14. Schulte C, Dignass AU, Mann K, et al. Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. Scand J Gastroenterol. 1999; 34: 696-702.
15. Guerreiro CS, Ferreira P, Tavares L, et al. Fatty acids, IL-6 and TNF-α polymorphisms: an example of nutrigenetics in Crohn's disease. Am J Gastroenterol. 2009; 104: 2241-2249.
16. Lennard Jones JE,. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989; 24 (suppl): 2-6.
17. Harvey RF, Bradshaw JM,. A simple index of Crohn's disease activity. Lancet. 1980; 1: 514.
18. Arroll B, Jackson R, Beaglehole,. Validation of a three-month physical activity recall questionnaire with a seven-day food intake and physical activity diary. Epidemiology. 1991; 2: 296-299.
19. Kanis JÁ, Gluer CC,. An update on the diagnosis and assessment of osteoporosis with densitometry. Committeee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int. 2000; 11: 192-202.
20. Bernstein CN, Leslie WD, Leboff MS,. AGA Technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003; 124: 795-841.
21. Lewiechi EM, Watts NB, McClung MR, et al. Official position of the International Society for Clinical Densitometry. J Clin Endocrinol Metabol. 2004; 89: 3651-3655.
22. Binkley N, Bilezikian JP, Kendler DL, et al. Summary of the International Society for Clinical Densitometry 2005 position development conference. J Bone Miner Res. 2007; 22: 643-647.
23. Reprodutibilidade e validação do questionário semiquantitativo de frequência alimentar. In Alimentação e Enfarte Agudo do Miocárdio: estudo caso-controlo de base comunitária. Tese de Doutoramento; Porto 2000. p 78-115.
24. Capprill R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut. 2006; 55:(suppl 1): I35-58.
25. Bernstein CN, Leslie WD,. The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol. 2003; 15: 857-864.
26. Lee N, Radford-Smith GL, Forwood M, et al. Body composition and muscle strength as predictors of bone mineral density in Crohn's disease. J Bone Miner Metab. 2009; 27: 456-463.
27. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines. Arthritis Rheum. 1996; 39: 1791-1801.
28. Motley RJ, Crawley EO, Evans C, et al. Increased rate of spinal trabecular bone loss in patients with inflammatory bowel disease. Gut. 1988; 29: 1332-1336.
29. Schoon EJ, Blok BM, Geerling BJ, et al. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology. 1997; 7: 909-920.
30. Gassull MA, Fernandez-Banares F, Cabre E, et al. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomized multicentre European trial. Gut. 2002; 51: 64-68.
31. MacLean CH, Mojica WA, Newberry SJ, et al. Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease. Am J Clin Nutr. 2005; 82: 611-619.
32. Esteve-Comas M, Gassull MA,. Abnormal fatty acid status in patients with Crohn disease. Am J Clin Nutr. 2001; 73: 661-662 [Letter].
33. Cabre E, Gassull MA,. Nutritional and metabolic issues in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care. 2003; 6: 569-576.
34. Belluzzi A, Bringole C, Campieri M, et al. Effects of an enteric coated fish oil preparation on relaps in Crohns disease. N Engl J Med. 1996; 334: 1557-1560.
35. MacLean CH, Mojica W, Newberry SJ, et al. Systematic review of effects of n-3 fatty acids in inflammatory bowel disease. Am J Clin Nutr. 2005; 82: 611-619.